on Optune at December 31, 2018, representing 24 percent growth compared to December 31, 2017.
In Germany and other EMEA markets, there were
654 active patients
on Optune at December 31, 2018, representing 28 percent growth compared to December 31, 2017.
In Japan, there were
92 active patients
on Optune at December 31, 2018, representing significant growth in the first year with reimbursement approval for Optune in Japan.
There were
1,315 prescriptions received
in the quarter ended December 31, 2018, representing 21 percent growth compared to the same period in 2017, and 6 percent growth compared to the quarter ended September 30, 2018.
Prescriptions for newly diagnosed GBM continued to grow, with approximately 950 Optune prescriptions in the fourth quarter written for patients with newly diagnosed GBM.
In the United States,
941 prescriptions
were received in the quarter ended December 31, 2018, representing 16 percent growth compared to the same period in 2017.
In Germany and other EMEA markets,
322 prescriptions
were received in the quarter ended December 31, 2018, representing 15 percent growth compared to the same period in 2017.
In Japan,
52 prescriptions
were received in the quarter ended December 31, 2018, representing significant growth in the first year with reimbursement approval for Optune in Japan.
News 
Market Data 
Discover 
